4
Changes in Ownership
CYTOKINETICS INC Filed Acc 0001127602-24-008501
EVP Research & Development sold 32,604 shares at an average $67.56 ($2,202,606)
- EVP Research & Development acquired 28,604 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Malik Fady Ibraham · EVP Research & Development
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-03-05 | Sale : show line 1 in the form 10b5-1 | −4,000 | $67.53 | $270,120 | 138,973 | D |
| 2024-03-05 | Exercise or conversion : show line 2 in the form 10b5-1 | +28,604 | $6.67 | $190,789 | 167,577 | D |
| 2024-03-05 | Sale : show line 3 in the form 10b5-1 | −28,604 | $67.56 | $1,932,486 | 138,973 | D |
| Open-market sales · 32,604 sh · avg $67.56 · $2,202,606 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-03-05 | Exercise or conversion : show line 4 in the form 10b5-1 Non-Qualified Stock Option (Right to Buy) | −28,604 | 28,605 | D |
Loading xslF345X05/form4.xml…